ShirishMadhavGadgeelMD

Hematologic Oncology, Thoracic Cancer

Chief, Division of Hematology & Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Hospital

Join to view full profile

Dr. Gadgeel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gadgeel's full profile

Already have an account?

Office
2799 W Grand Blvd, Hematology/Oncology-CFP-5
Same
Detroit, MI 48202
Phone+1 313-916-9365

Fax+1 313-916-3711
Is this information wrong?

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1996 - 2000
Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1996
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1993 - 1994
Grant Medical CollegeClass of 1992

Certifications & Licensure

MI State Medical License 1995 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2003 Aug 01
Completed
Not Applicable
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 2
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 2
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 2
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Completed
Phase 1
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Mar 01
Terminated
Phase 2
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
Suspended
Not Applicable
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Not Applicable
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Recruiting
Not Applicable
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy Start of enrollment: 2015 Jun 29
Terminated
Phase 2
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Start of enrollment: 2015 Sep 08
Completed
Phase 1
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2016 Jul 18
Active, not recruiting
Phase 2
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Start of enrollment: 2019 Sep 21
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Start of enrollment: 2021 Nov 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Roles: Contact
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Start of enrollment: 2020 Nov 03
Terminated
Phase 2
Roles: Contact, Principal Investigator
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 19
Terminated
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of O...
Delvys Rodríguez-Abreu, Takayasu Kurata, Ying Cheng, Erin Jensen, Mark Shamoun, Kumar Rajagopalan, Luis Paz-Ares, Shirish M Gadgeel, Balazs Halmos, Marina C Garassino> ;Journal of Thoracic Oncology. 2024 Apr 18
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.
Srinivas Annavarapu, Sartaj Alam, Melissa Santorelli, Renata Eiras Martins, Shirish M Gadgeel, Pragya Rai, Jerome H Goldschmidt, Howard Jack West> ;Frontiers in Oncology. 2024 Jan 1
Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
Elaine M Jennings, D Ross Camidge, Shirish Gadgeel, Scott Barker> ;Clinical Lung Cancer. 2024 Mar 1
1 citations
Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT).
Nitin Ohri, Shruti Jolly, Benjamin T Cooper, Rafi Kabarriti, William R Bodner, Jonathan Klein, Chandan Guha, Shankar Viswanathan, Elaine Shum, Joshua K Sabari, Haiying...> ;Journal of Clinical Oncology. 2024 Feb 10
ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Luis F Gonzalez-Mosquera, Fawzi Abu Rous, Alexandra Rogers, Nicolina Smith, Gregory Goyert, Shirish Gadgeel> ;Clinical Lung Cancer. 2024 Mar 1
1 citations
A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Angel Qin, Leah Wells, Binu Malhotra, Shirish Gadgeel, Bryan J Schneider, Nithya Ramnath, John D Rice, Gregory P Kalemkerian> ;Clinical Lung Cancer. 2024 Mar 1
Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations.
Matthew R Trendowski, Christine M Lusk, Angela S Wenzlaff, Christine Neslund-Dudas, Shirish M Gadgeel, Ayman O Soubani, Ann G Schwartz> ;Cancer Epidemiology, Biomarkers & Prevention. 2023 Nov 1
Race-Associated Genomic Correlates of Therapeutic Response in African American Patients With Non-Small-Cell Lung Cancer.
Pin Li, Kaitlyn Kane, Frank M Wolf, Anna B Berry, Shirish Gadgeel, Amanda Pilling> ;JCO Precision Oncology. 2023 Aug 1
1 citations
Corrigendum to "Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYN...
Edward B Garon, Joachim Aerts, Jong Seok Kim, Catherine E Muehlenbein, Patrick Peterson, Maria Teresa Rizzo, Shirish M Gadgeel> ;Lung Cancer. 2023 Sep 1
6 citations
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases.
Marcelo V Negrao, Alexander I Spira, Rebecca S Heist, Pasi A Jänne, Jose M Pacheco, Jared Weiss, Shirish M Gadgeel, Karen Velastegui, Wenjing Yang, Hirak Der-Torossian...> ;Journal of Clinical Oncology. 2023 Oct 1
10 citations
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy.
Alexander Drilon, Manish R Sharma, Melissa L Johnson, Timothy A Yap, Shirish Gadgeel, Dale Nepert, Gang Feng, Micaela B Reddy, Allison S Harney, Mohamed Elsayed, Adam ...> ;Cancer Discovery. 2023 Aug 4
1 citations
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042).
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, N...> ;Clinical Cancer Research. 2023 Sep 15
Brief Report: Prognostic Relevance of 3q Amplification in Squamous Cell Carcinoma of the Lung.
Fawzi Abu Rous, Pin Li, Shannon Carskadon, Sunny Rk Singh, Rebecca Chacko, Hassan Abushukair, Shirish Gadgeel, Nallasivam Palanisamy> ;JTO Clinical and Research Reports. 2023 Apr 1
7 citations
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
Kai He, David Berz, Shirish M Gadgeel, Wade T Iams, Debora S Bruno, Collin M Blakely, Alexander I Spira, Manish R Patel, David M Waterhouse, Donald A Richards, Anthony...> ;Journal of Thoracic Oncology. 2023 Jul 1
67 citations
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
Marina C Garassino, Shirish Gadgeel, Giovanna Speranza, Enriqueta Felip, Emilio Esteban, Manuel Dómine, Maximilian J Hochmair, Steven F Powell, Helge G Bischoff, Nir P...> ;Journal of Clinical Oncology. 2023 Apr 10
1 citations
Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
Monika A Izano, Connor Sweetnam, Chenan Zhang, James L Weese, Douglas Reding, Jonathan Treisman, Anand Patel, Bindu Potugari, Andrew Stafford, Frank M Wolf, Mary Tran,...> ;Clinical Lung Cancer. 2023 Jun 1
Clinical Outcome in Patients With Early-Stage Small Cell Lung Cancer Treated With Surgery or Radiation in the Absence of Prophylactic Cranial Irradiation: A Single-Cen...
Sondos Al Khatib, Khalid Adil, Lonni Schultz, Shirish Gadgeel, Andrew Popoff, Munther Ajlouni, Michael Simoff, Benjamin Movsas, Aharon Feldman> ;Advances in Radiation Oncology. 2023 Feb 6
38 citations
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.
Luis Paz-Ares, Stephane Champiat, W Victoria Lai, Hiroki Izumi, Ramaswamy Govindan, Michael Boyer, Horst-Dieter Hummel, Hossein Borghaei, Melissa L Johnson, Neeltje St...> ;Journal of Clinical Oncology. 2023 Jun 1
Daclatasvir, an Antiviral Drug, Downregulates Tribbles 2 Pseudokinase and Resensitizes Enzalutamide-Resistant Prostate Cancer Cells.
Jitender Monga, Frederick Valeriote, Clara Hwang, Shirish Gadgeel, Jagadananda Ghosh> ;Molecular Cancer Therapeutics. 2023 Mar 2
Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics.
Tiffany A Ho, Katelyn M Patterson, Shirish M Gadgeel, Rachel M Kenney, Michael P Veve> ;Antimicrobial Stewardship & Healthcare Epidemiology. 2023 Jan 1
11 citations
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC.
Marina C Garassino, Shirish Gadgeel, Silvia Novello, Balazs Halmos, Enriqueta Felip, Giovanna Speranza, Rina Hui, Edward B Garon, Hidehito Horinouchi, Shunichi Sugawar...> ;JTO Clinical and Research Reports. 2023 Jan 1
High-dose alectinib forfusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Dziadziuszko, R., Peled, N., Mok, T., Peters, S., Aix, S., Alatorre-Alexander, J., Maclennan, M., Bhagawati-Prasad, V., Shagan, S., Schleifman, E., Ruf, T., Mathisen, ...> ;Contemporary Oncology. 2023 Jan 1
2 citations
Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management.
Houssein Safa, Fawzi Abu Rous, Neel Belani, Hossein Borghaei, Shirish Gadgeel, Balazs Halmos> ;Targeted Oncology. 2023 Jan 1
Join now to see all

Lectures

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
Management of Immunotherapy Toxicities in Patients With Lung Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Second-Line Treatment Options in Non-Small Cell Lung Cancer (NSCLC): Report from an International Experts Panel Meeting of the Italian Association of Thoracic OncologyDecember 2017

Press Mentions

A Second KRAS Inhibitor: FDA Grants Accelerated Approval to Adagrasib in NSCLCDecember 13th, 2022
$7.6 Million Gift Launches New Lung Cancer Research Initiative at U-mJanuary 13th, 2022
World Renowned Medical Oncologist Joins Henry Ford Cancer InstituteJanuary 6th, 2022
Join now to see all